Stem Cell Dialogues: “Stem Cell Therapies for Chronic Pain.” This is a video of the Feb. 7, 2012 event, which is part of UC Davis Health System’s ongoing series of community forums about stem cell research. The session features research and clinical experts Jan Nolta, director of the UC Davis Institute for Regenerative Cures; Scott Fishman, chief of the UC Davis Division of Pain Medicine; and Kee Kim, Co-director of the UC Davis Spine Center. Presenters discuss the challenges of treating chronic pain and the latest research and treatment opportunities using regenerative medicine. The session includeds a Question and Answer session with audience members. Stem Cell Dialogues is moderated by Dr. Fred Meyers, executive associate dean of the UC Davis School of Medicine.
Olga Momcilovic speaks at the 2011 CIRM Grantee Meeting about the use of induced pluripotent stem (iPS) cells to better understand the causes of Parkinson’s and to develop therapies. Momcilovic is a CIRM Scholar and postdoctoral research fellow at the Buck Institute located in Novato, California.
Go See Improved Adult Stem Cell Circulation … morris.stemtechbiz.com …Now… with the new Adult Stem cell Circulation Enhancer Capsules… Stem Cell Nutrition will better aid the circulation and help with getting oxygen to all parts of the body! Stem Cell Circulation Enhancer capsules are a new phytoceutical product, that can help improve stem cell trafficking. Powerful antioxidants help reduce the oxidative stress in the body’s blood physiology, reducing the formation of fibrin mesh: and contains a blend of enzymes that help digest the fibrin within the blood. This combination helps support optimizing a more free-flowing circulation. Along with nutrients .. this stem cell circulation formula supports the delivery of nutrients and oxygen to the body as well as the stem cells!
In a boost for the field of regenerative medicine, a small biotechnology company has received regulatory approval in Canada for what it says is the first manufactured drug based on stem cells.
The company, Osiris Therapeutics of Columbia, Md., said Thursday that Canadian regulators had approved its drug Prochymal, to treat children suffering from graft-versus-host disease, a potentially deadly complication of bone marrow transplantation.
“It’s really a good day for the concept and the hope behind stem cell therapies becoming a reality,” C. Randal Mills, the chief executive of Osiris, said in an interview.
Prochymal is a preparation of mesenchymal stem cells, which are obtained from the bone marrow of healthy young adult donors. The stem cells are separated out from the marrow and expanded in culture, so that one donation is enough to make as many as 10,000 doses.
Because these are adult stem cells, they do not raise the ethical concerns of embryonic stem cells, whose creation usually involves the destruction of human embryos.
Graft-versus-host disease occurs when the immune cells in a bone-marrow transplant see the recipient’s organs as foreign and attack them, causing potentially severe damage to the skin, liver and digestive tract. This happens most often when the donor is not an exact match for the recipient.
Doctors try using steroids or other drugs to damp the immune attack, but in many cases those don’t work, and the patient may die.
Prochymal is approved in Canada for children whose condition is not controlled by steroids. In a small trial, about 60 percent of such children had a clinically meaningful response to the drug, Osiris said.
“Any drug or a cell that has activity in the patients with severe disease is exciting and important,” said Dr. Joanne Kurtzberg, director of the pediatric blood and marrow transplant program at Duke University Medical Center.
Dr. Kurtzberg, who helped Osiris present its case to Canadian regulators, said the drug has saved some children’s lives from graft-versus-host disease and could lead to more successful bone marrow transplants.
Osiris is not expected to gain much revenue from patients with a rare disease in Canada. But it is a welcome success for a 20-year-old company that has had its share of failures.
In 2009, Prochymal failed in two late-stage clinical trials, showing little to no advantage over placebo in treating graft-versus-host disease. The company is also trying to develop Prochymal as a treatment for Crohn’s disease, diabetes, heart attacks and other illnesses, but has had some failures there as well.
Sanofi, the big French company that had the rights to sell Prochymal outside North America, said in February that it had discontinued its work on the drug.
Dr. Mills, Osiris’s chief executive, said the company realized the drug was most effective in the most severe cases of graft-versus-host-disease that did not respond to steroids, leading it to do the small trial in children.
Dr. Mills said that the Food and Drug Administration indicated that it would require more data before approval, prompting Osiris to seek approval in Canada first. He said the company would apply to the F.D.A. later this year.
Stem cells are already used in medicine. Bone marrow or stem cell transplants are used to treat various cancers and genetic diseases. But those transplants are medical procedures, not products sold by a drug company.
There are cell therapies that have been approved by regulators, such as Carticel, a Genzyme product that uses a patient’s own cells to repair cartilage in injuries. Last year the F.D.A. approved a cord blood product for use in transplantation. Those products are not manufactured for off-the-shelf use like Prochymal is, Dr. Mills said.
Since the original publication of Allogeneic Stem Cell Transplantation: Clinical Research and Practice, Allogeneic hematopoietic stem cell transplantation (HSC) has undergone several fast-paced changes. In this second edition, the editors have focused on topics relevant to evolving knowledge in the field in order to better guide clinicians in decision-making and management of their patients, as well as help lead laboratory investigators in new directions emanating from clinical observations. Som
Witness Releasing Millions MORE Adult Stem Cells Naturally .. go to EJMorris.biz .. If a person stimulates the body to Release MORE stem cells from the bone marrow, the body would likely be able to repair and renew itself, at a balanced.. or Faster pace than it might by dying. Negative changes in the body, due to illness, accident or simply going through process of aging.. results in less adult stem cells circulating in the blood stream. Investigate All your adult stem cell therapy options, including patented natural adult stem cell enhancer capsules and the category of adult stem cell nutrition. Fact The more adult stem cells in the bloodstream are, the better it is for the body.. the closer you are to achieving optimal health. Fact: The older the body becomes.. MORE adult Stem Cells are required for repair and Renewal. And, the sad fact is.. as the body AGES .. the body has LESS stem cells in blood circulation for renewal ,repair and rejuvenation. The World’s FIRST Adult stem cell nutrition that releases, into circulation into the blood stream, millions more adult stem cells that are “Stuck” in the bone marrow is phenomenon that adult stem cell scientists and researchers have discovered. It has been proven our OWN adult stem cells.. the stem cells that are present in our body from the Minute we are born, constitute our body’s natural RENEWAL SYSTEM. Witness the world’s first adult stem cell enhancer nutrition products available in capsules, tablets, powders, granules …
www.globalchange.com Repair retina damaged by macular degeneration in the eye. Retinal regeneration using adult stem cells – research and early clinical trials. Other studies using embryonic stem cells to partially restore sight in those with visual impairment blindness. Use of adult neural stem cells from the olfactory bulb to treat brain disease, brain injury or spinal cord injury, paralysis. Antiageing therapies, science and research. 65% of health care spending on people over 65 years old. Aging process — physiology of aging and remedies, antiaging therapies. How to stay young. How we share common aging and regenerative processes with many other animals. Shared genetic code and cell structures. From health to performance, from sickness to wellness, from prevention to appearance, from rehabilitation to organ regeneration. Future of health care. Patrick Dixon is a health care keynote speaker at many health conferences.
In a boost for the field of regenerative medicine, a small biotechnology company has received regulatory approval in Canada for what it says is the first manufactured drug based on stem cells.
(out of reviews)
